1,604 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Symmetry Partners LLC

Symmetry Partners LLC bought a new position in shares of Biogen Inc. (NASDAQ:BIIBGet Rating) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,604 shares of the biotechnology company’s stock, valued at approximately $327,000.

Other hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in shares of Biogen in the 1st quarter valued at $823,000. TownSquare Capital LLC boosted its holdings in shares of Biogen by 31.9% in the 1st quarter. TownSquare Capital LLC now owns 11,978 shares of the biotechnology company’s stock valued at $2,522,000 after purchasing an additional 2,894 shares during the last quarter. AIA Group Ltd boosted its holdings in shares of Biogen by 42.2% in the 1st quarter. AIA Group Ltd now owns 2,197 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 652 shares during the last quarter. IndexIQ Advisors LLC boosted its holdings in shares of Biogen by 6.5% in the 1st quarter. IndexIQ Advisors LLC now owns 3,014 shares of the biotechnology company’s stock valued at $636,000 after purchasing an additional 185 shares during the last quarter. Finally, Stephens Inc. AR boosted its holdings in shares of Biogen by 18.5% in the 4th quarter. Stephens Inc. AR now owns 18,947 shares of the biotechnology company’s stock valued at $4,546,000 after purchasing an additional 2,952 shares during the last quarter. Institutional investors and hedge funds own 83.45% of the company’s stock.

Biogen Trading Up 0.7 %

NASDAQ BIIB opened at $208.26 on Monday. Biogen Inc. has a one year low of $187.16 and a one year high of $304.21. The company has a 50-day simple moving average of $210.00 and a 200-day simple moving average of $207.17. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.68 and a current ratio of 1.94. The firm has a market capitalization of $30.22 billion, a PE ratio of 14.85, a price-to-earnings-growth ratio of 0.95 and a beta of 0.43.

Biogen (NASDAQ:BIIBGet Rating) last posted its quarterly earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 EPS for the quarter, beating the consensus estimate of $4.09 by $1.16. Biogen had a net margin of 19.36% and a return on equity of 22.36%. The business had revenue of $2.59 billion during the quarter, compared to analyst estimates of $2.48 billion. During the same period in the previous year, the business posted $5.68 EPS. The company’s quarterly revenue was down 6.7% on a year-over-year basis. On average, equities analysts forecast that Biogen Inc. will post 16.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Barclays cut their target price on shares of Biogen from $210.00 to $200.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 21st. Stifel Nicolaus cut their target price on shares of Biogen from $230.00 to $223.00 and set a “hold” rating on the stock in a research note on Monday, September 12th. UBS Group cut their target price on shares of Biogen to $238.00 in a research note on Friday, July 22nd. Cowen cut their target price on shares of Biogen from $285.00 to $270.00 and set an “outperform” rating on the stock in a research note on Thursday, July 21st. Finally, Cowen cut their target price on shares of Biogen from $285.00 to $270.00 in a research note on Thursday, July 21st. Thirteen research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $257.36.

Biogen Profile

(Get Rating)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Featured Articles

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIBGet Rating).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.